Approved Study Database

Ref. No. Scientific Title Principal investigator
2013.284 Detection of Cerebral Autoregulation in Patients witih Supertentorial Intracerbral Hemorrhage Using Transcranial Doppler Ultrasonography DR CHAN KIT YING
2026.574 Among women who have undergone mastectomy (with or without reconstruction), does nurse-led 3D Nipple-Areola Complex (NAC) tattooing improve patient-reported outcomes—assessed using the BREAST-Q Reconstruction Module—such as aesthetic satisfaction and quality of life, within 6 months? Ms. CHAN KOVIE KA WING
2008.166 Investigationof the Genomic Representation of Fetal DNA in the Plasma of Pregnant Women Prof CHAN Kwan Chee Allen
2010.021 Investigation into the association between the presence of methylate tumour suppressor gene sequences in serum and the risk of developing hepatocellular carcinoma in chronic hepatitus B carriers Prof CHAN Kwan Chee Allen
2008.024 Investigation on the Long and Short-term Variations of Plasma Epstein-Barr Virus (EBV) DNA in Healthy Subjects Prof Chan Kwan Chee Allen
2025.749 Comparing diagnostic performance of 3D T1 VIBE MR sequence to CT for the detection of radiographically occult fractures of the hip and pelvis Dr. CHAN Kwan Kit
2012.508 Psychiatric and physical comorbidities among primary care insomniacs in Hong Kong Dr. Chan Kwok Keung
2008.430 Comparison of the Accuracy of Bernese Ankle Rules and Ottawa Ankle Rules in Ruling Out Ankle and Mid-Foot Fractures of Adults in Twisting Ankle and Foot Injury. A Prospective Cross Sectional Study Ms CHAN LAI MAN
2011.529 Effectiveness of warm lignocaine in reducing infiltration pain during digital nerve block injection: A randomized controlled trial. Ms CHAN LAI MAN
2010.564 A Randomized Phase III study of Oxaliplatin (Eloxatin) and Capecitabine on top of Sorafenib versus Sorafenib alone as first-line palliative treatment in advanced hepatocellular carcinoma patients ineligible for curative resection or local treatment Prof Chan Lam
2025.833 Clinical Utility of the Treatment-related Toxicity Risk Model (TRTRM) in Older Patients with Cancer: a Randomised Controlled Trial Dr. Chan Lam
2016.085 A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy Dr. CHAN Lam
陳林
2015.459 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects with Advanced Hepatocellular Carcinoma Prof. CHAN Lam
陳林
2010.563 An open-label, randomized, multi-center, phase II study to compare the safety and efficacy of TKI258 versus sorafenib as first-line treatment in adult patients with advanced hepatocellular carcinoma Assistant Professor Chan Lam, Stephen
2011.145 The use of circulating methylated RASSF1A in prognostication and monitoring of treatment response for inoperable hepatocellular carcinoma Dr. Chan Lam, Stephen
2024.311 Stereotactic Body Radiotherapy with Immunotherapy (Atezolizumab plus Bevacizumab) in Patients with Advanced HCC and Major Portal Vein Tumour Thrombosis Dr. CHAN Landon
Stephen Lam CHAN
2024.326 Impact of Radiotherapy on the Dynamic Changes of Circulating Cell-free DNA in Patients with Hepatocellular Carcinoma Dr. CHAN Landon
2026.420 IMPACT 31: A Randomized Open-label, Multi-center, Phase II Adjuvant Study of a Personalized Neoantigen DNA Vaccine (GNOS-PV02) and Plasmid encoded IL-12 (INO-9012) versus Active Surveillance in Subjects with High-Risk Hepatocellular Carcinoma Dr Chan Landon Long
2026.565 Study on the outcome of lenvatinib treated in patients’ journey of hepatocellular carcinoma Dr. Chan Landon Long
2026.595 A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF VVD-133214 IN COMBINATION WITH PEMBROLIZUMAB COMPARED TO PEMBROLIZUMAB MONOTHERAPY IN PARTICIPANTS WITH ADVANCED COLORECTAL ADENOCARCINOMA (CRC) HARBORING MICROSATELLITE INSTABILITY (MSI) AND/OR DEFICIENT MISMATCH REPAIR (DMMR) Dr. Chan Landon Long
2017.533 Prevalence of neuromyelitis optica in Hong Kong Dr. CHAN Larry Wai Lun
陳偉麟
2014.410 End-of-life decisions in Neonatal Intensive Care Unit: A Retrospective Analysis of Modes of Deaths in the NICU Dr CHAN Lawrence Chi Ngong
2019.175 Variation in intensive care practices for moderate to severe traumatic brain injury Dr. CHAN Lawrence Chi Ngong
陳子昂
2015.512 Effect of a structured aerobic exercise programme in managing fatigue among community dwelling older adults with multicomorbidities by a prospective randomized controlled trial Mr. CHAN Leong Tat
陳亮達
2014.626 Evaluation of the psychometric properties of the Chinese version of the Multidimensional Fatigue Inventory among community dwelling older adults with multicomorbidities by a non-experimental, prospective, descriptive, correlation study design Mr Chan Leong Tat
2008.168 A Functional Study of An Epithelial-Mesenchymal Transition Regulatory Transcription Factor Snail in Prostate Cancer Prof. Chan Leung Franky
2010.579 Functional roles of an orphan nuclear receptor Tailless TLX in advanced prostate cancer Prof CHAN Leung Franky
2017.328 A PHASE I, SPONSOR-OPEN, INVESTIGATOR-BLINDED, SUBJECT-BLINDED, MULTI-CENTER, PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ORAL ADMINISTRATION OF RO7020531: (1). SINGLE AND MULTIPLE ASCENDING DOSES IN HEALTHY MALE AND FEMALE SUBJECTS; (2). 6-WEEK TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION Prof. CHAN Lik Yuen
陳力元
2017.177 A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching from Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects with Chronic Hepatitis B who are Virologically Suppressed Dr. CHAN Lik Yuen
陳力元
2016.089 A MULTIPLE-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE AND MULTIPLE-ASCENDING DOSE, ADAPTIVE PARALLEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7020322 FOLLOWING ORAL ADMINISTRATION IN HEALTHY SUBJECTS AND CHRONIC HEPATITIS B PATIENTS Dr. CHAN Lik Yuen
陳力元
2015.124 A MULTIPLE-CENTER, RANDOMIZED, PARTIALLY DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTIVIRAL EFFECTS OF 12-WEEK TREATMENT WITH RO6864018 IN VIROLOGICALLY SUPPRESSED PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION Prof. CHAN Lik Yuen
陳力元
2013.115 An Open Label, Phase 2a, Single-Arm Study of the Antifibrotic Activity of FG-3019 in Subjects with Advanced Liver Fibrosis due to Chronic Hepatitis C Infection (HCV) Prof Chan Lik Yuen Henry
2012.046 Serum hepatitis B surface antigen levels to guide the stopping of entecavir in HBeAg-negative chronic hepatitis B Prof Chan Lik Yuen Henry
2012.536 A multicenter open-label study to evaluate the safety and efficacy of PEG-Intron™ versus PEGASYS™ in subjects with HBeAg positive chronic hepatitis B and HBeAg negative chronic hepatitis B Prof. Chan Lik Yuen Henry
2010.498 Dose-Ranging Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Pegylated Interferon Lambda (BMS-914143) Monotherapy in Interferon-Naive Patients with Chronic Hepatitis B Virus Infection who are HBeAg-positive Prof CHAN Lik Yuen, Henry
2011.429 Alcohol Related Liver Damage in Hong Kong Prof. Chan Lik Yuen, Henry
2010.286 Efficacy of entecavir or tenofovir in chronic hepatitis B patients with lamivudine resistance suboptimal virological response to adefovir Prof Chan Lik Yuen, Henry
2008.367 Development of a Non-Invasive Algorithm for Advanced Liver Fibrosis in Chronic Hepatitis B Prof. Chan Lik Yuen, Henry
2012.176 The effect of Telbivudine on renal function and proteinuria in patients with chronic hepatitis B infection and chronic kidney diseases Prof. Chan Lik-Yuen Henry
2010.599 A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL PF-04136309 500MG BID IN SUBJECTS WITH CHRONIC HCV INFECTION AND RAISED AMINOTRANSFERASES Prof Chan Lik-yuen Henry
2013.015 Are Hong Kong Construction Workers physically fit to perform jobs? A Cross-sectional study Mr Chan Lok Hang
2024.039 Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma with Oligoprogression on First-line Immunotherapy Dr. CHAN Long
2011.436 Uptake rate and determinants for influenza vaccination in a local general out-patient clinic in Hong Kong Dr Chan Man Hung
2005.191 Psychiatric Morbidity and Health-Related Quality of Life in Parkinson's Disease CHAN Man Lui
2020.580 Effect of foot orthotic intervention on postural stability of elderly -a pilot study Mr. CHAN Man Lung
2013.328 A pilot study on effectiveness of self-efficacy based educational programme on maternal breastfeeding self-efficacy and breastfeeding duration: A longitudinal, randomized controlled study. Ms Chan Man Yi
2020.048 The effectiveness of Crew Resource Management based Simulation Training (CRM-ST) program in improving student midwives’ performance in management of primary postpartum haemorrhage: a randomized controlled trial Dr CHAN Man Yi
陳敏兒
2020.346 Prevalence and Monitoring of Psychiatric Out-patients Taking High-Dose Antipsychotic therapy (HDAT) in Hong Kong Ms. CHAN Mandy Man Ting
2013.239 Laboratory discovery of novel viruses associated with acute neurological illness using residual routine cerebrospinal fluid specimens of unknown etiology Dr. CHAN Martin Chi Wai
2013.330 Laboratory detection of novel norovirus strain(s) using residual routine diagnostic stool specimens Dr. CHAN Martin Chi Wai

Page 57 of 288.